Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands;
Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.
J Nucl Med. 2021 Oct;62(10):1357-1362. doi: 10.2967/jnumed.120.246819. Epub 2021 Feb 26.
Sentinel lymph node (SN) biopsy (SNB) has proven to be a valuable tool for staging melanoma patients. Since its introduction in the early 1990s, this procedure has undergone several technologic refinements, including the introduction of SPECT/CT, as well as radioguidance and fluorescence guidance. The purpose of the current study was to evaluate the effect of this technologic evolution on SNB in the head and neck region. The primary endpoint was the false-negative (FN) rate. Secondary endpoints were number of harvested SNs, overall operation time, operation time per harvested SN, and postoperative complications. A retrospective database was queried for cutaneous head and neck melanoma patients who underwent SNB at The Netherlands Cancer Institute between 1993 and 2016. The implementation of new detection techniques was divided into 4 groups: 1993-2005, with preoperative lymphoscintigraphy and intraoperative use of both a γ-ray detection probe and patent blue ( = 30); 2006-2007, with addition of preoperative road maps based on SPECT/CT ( = 15); 2008-2009, with intraoperative use of a portable γ-camera ( = 40); and 2010-2016, with addition of near-infrared fluorescence guidance ( = 192). In total, 277 patients were included. At least 1 SN was identified in all patients. A tumor-positive SN was found in 59 patients (21.3%): 10 in group 1 (33.3%), 3 in group 2 (20.0%), 6 in group 3 (15.0%), and 40 in group 4 (20.8%). Regional recurrences in patients with tumor-negative SNs resulted in an overall FN rate of 11.9% (group 1, 16.7%; group 2, 0%; group 3, 14.3%; group 4, 11.1%). The number of harvested nodes increased with advancing technologies ( = 0.003), whereas Breslow thickness and operation time per harvested SN decreased ( = 0.003 and = 0.017, respectively). There was no significant difference in percentage of tumor-positive SNs, overall operation time, and complication rate between the different groups. The use of advanced detection technologies led to a higher number of identified SNs without an increase in overall operation time, possibly indicating an improved surgical efficiency. Operation time per harvested SN decreased; the average FN rate remained 11.9% and was unchanged over 23 y. There was no significant change in postoperative complication rate.
前哨淋巴结(SN)活检(SNB)已被证明是一种用于分期黑色素瘤患者的有价值的工具。自 20 世纪 90 年代初引入以来,该技术经历了多次技术改进,包括 SPECT/CT 的引入,以及放射性和荧光引导。本研究的目的是评估该技术发展对头颈部 SNB 的影响。主要终点是假阴性(FN)率。次要终点是收获的 SN 数量、总手术时间、每个收获的 SN 的手术时间以及术后并发症。 从荷兰癌症研究所 1993 年至 2016 年间接受 SNB 的皮肤头颈部黑色素瘤患者的回顾性数据库中查询。新检测技术的实施分为 4 组:1993-2005 年,术前淋巴闪烁显像术和术中同时使用γ射线探测探头和专利蓝(=30);2006-2007 年,添加基于 SPECT/CT 的术前路线图(=15);2008-2009 年,术中使用便携式γ相机(=40);2010-2016 年,添加近红外荧光引导(=192)。 总共纳入了 277 名患者。所有患者均至少发现了 1 个 SN。59 名患者(21.3%)发现肿瘤阳性 SN:第 1 组 10 名(33.3%),第 2 组 3 名(20.0%),第 3 组 6 名(15.0%),第 4 组 40 名(20.8%)。肿瘤阴性 SN 患者的区域复发导致总 FN 率为 11.9%(第 1 组 16.7%;第 2 组 0%;第 3 组 14.3%;第 4 组 11.1%)。随着技术的进步,收获的节点数量增加(=0.003),而 Breslow 厚度和每个收获的 SN 的手术时间减少(=0.003 和=0.017,分别)。不同组之间肿瘤阳性 SN 百分比、总手术时间和并发症发生率无显著差异。 先进检测技术的使用导致识别的 SN 数量增加,而总手术时间没有增加,这可能表明手术效率提高。每个收获的 SN 的手术时间减少;平均 FN 率在 23 年内保持在 11.9%,保持不变。术后并发症发生率无显著变化。